# Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

> **NCT03258931** · PHASE3 · COMPLETED · sponsor: **Arog Pharmaceuticals, Inc.** · enrollment: 214 (actual)

## Conditions studied

- Newly Diagnosed FLT3 Mutated AML

## Interventions

- **DRUG:** Crenolanib
- **DRUG:** Midostaurin
- **DRUG:** Cytarabine
- **DRUG:** Duanorubicin

## Key facts

- **NCT ID:** NCT03258931
- **Lead sponsor:** Arog Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-15
- **Primary completion:** 2026-04-06
- **Final completion:** 2026-04-06
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03258931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03258931, "Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03258931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*